Eli Lilly to Acquire Seattle-Area Biotech in $1.5B Bet on Next-Generation Shingles Vaccine

Eli Lilly has acquired Curevo Vaccine, whose lead shingles vaccine candidate incorporates AAHI’s proprietary SLA-SE adjuvant. The deal highlights growing recognition of next-generation vaccine technologies and is one of three acquisitions announced last week as Lilly expands its infectious disease portfolio.